Skip to main content
Premium Trial:

Request an Annual Quote

Ghent to Use Roche's LightCycler in Cancer Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Scientists at Ghent University in Belgium will use Roche's LightCycler 1536 in various cancer research projects, the company said today.

Ghent researchers will use the technology for multi-gene expression signature profiling on cancer research samples and for digital PCR for sensitive detection of mutant cancer cells in a background of normal cells.

The school also will use the LightCycler in studies involving DNA methylation analysis, copy number variant screening, and amplicon generation for next-generation sequencing efforts. One study will use qPCR-based transcriptome-wide profiling in a pilot experiment that will involve measuring genes in reference RNA samples, said Roche.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.